A retrospective longitudinal cohort study of antihypertensive drug use and new-onset diabetes in taiwanese patients

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Huang, Ching Ya ^a,b   Ma, Tsochiang ^b   Tien, Liyun ^c   Hsieh, Yow Wen ^a,b   Lee, Shwu Yi ^d   Chen, Hung Yi ^a,b   Jong, Gwo Ping ^e  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Bureau of National Health Insurance Taiwan   (Taiwan)

^d Yuan Rung Hospital   (Taiwan)

^e CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES; RETROSPECTIVE STUDY; TAIWAN; MIDDLE AGED; RISK; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; DIURETICS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; THIAZIDES;

EID: 84874618464     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/287696     Document Type: Article

References (28)

1. Hu G., Jousilahti P., Tuomilehto J., Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. European Heart Journal 2007 28 24 3059 3066 2-s2.0-37149050177 10.1093/eurheartj/ehm501 (Pubitemid 350262268)
2. Dall T., Mann S. E., Zhang Y., Martin J., Chen Y., Hogan P., Petersen M., Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008 31 3 596 615 2-s2.0-43449108812 10.2337/dc08-9017
3. Minshall M. E., Roze S., Palmer A. J., Valentine W. J., Foos V., Ray J., Graham C., Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clinical Therapeutics 2005 27 6 940 950 2-s2.0-27744561705 10.1016/j.clinthera.2005.06.006 (Pubitemid 41583533)
4. McFarlane S. I., Farag A., Sowers J., Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovascular Drug Reviews 2003 21 2 105 118 2-s2.0-0041663864 (Pubitemid 36935489)
5. Pepine C. J., Handberg E. M., Cooper-DeHoff R. M., Marks R. G., Kowey P., Messerli F. H., Mancia G., Cangiano J. L., Garcia-Barreto D., Keltai M., Erdine S., Bristol H. A., Kolb H. R., Bakris G. L., Cohen J. D., Parmley W. W., A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the international verapamil- trandolapril study (INVEST): a randomized controlled trial. Journal of the American Medical Association 2003 290 21 2805 2816 2-s2.0-0345492460 10.1001/jama.290.21.2805 (Pubitemid 37509488)
6. ALLHAT, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The Journal of the American Medical Association 2002 288 23 2981 2997
7. Morales P. A., Mitchell B. D., Valdez R. A., Hazuda H. P., Stern M. P., Haffner S. M., Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects: The San Antonio Heart Study. Diabetes 1993 42 1 154 161 2-s2.0-0027441266 (Pubitemid 23013808)
8. Rajala U., Qiao Q., Laakso M., Keinänen-Kiukaanniemi S., Antihypertensive drugs as predictors of Type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Research and Clinical Practice 2000 50 3 231 239 2-s2.0-0033661766 10.1016/S0168-8227(00)00189-3
9. Weycker D., Edelsberg J., Vincze G., Kjeldsen S. E., Jamerson K., Khan Z. M., Oster G., Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. Journal of Human Hypertension 2007 21 5 374 380 2-s2.0-34247343986 10.1038/sj.jhh.1002159 (Pubitemid 46637944)
10. Ogihara T., Fujimoto A., Nakao K., Saruta T., ARB candesartan and CCB amlodipine in hypertensive patients: The CASE-J trial. Expert Review of Cardiovascular Therapy 2008 6 9 1195 1201 2-s2.0-55349147316 10.1586/14779072.6.9.1195
11. Jong G. P., Chang M. H., Tien L., Li S. Y., Liou Y. S., Lung C. H., Ma T., Antihypertensive drugs and new-onset diabetes: a retrospective longitudinal cohort study. Cardiovascular Therapeutics 2009 27 3 159 163 2-s2.0-68849115205 10.1111/j.1755-5922.2009.00092.x
12. Karnes J. H., Cooper-DeHoff R. M., Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Review of Cardiovascular Therapy 2009 7 6 689 702 2-s2.0-68849097702 10.1586/erc.09.31
13. McInnes G. T., The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors. Journal of Human Hypertension 2011 25 6 343 345 2-s2.0-79956114383 10.1038/jhh.2011.12
14. Elliott W. J., Differential effects of antihypertensive drugs on new-onset diabetes? Current Hypertension Reports 2005 7 4 249 256 2-s2.0-24944487294 (Pubitemid 41309540)
15. Padwal R., Laupacis A., Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004 27 1 247 255 2-s2.0-1042291850 10.2337/diacare.27.1.247 (Pubitemid 38196740)
16. Taylor E. N., Hu F. B., Curhan G. C., Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006 29 5 1065 1070 2-s2.0-33746367481 10.2337/diacare.2951065 (Pubitemid 44115245)
17. Scheen A. J., Renin-angiotensin system inhibition prevents type 2 diabetes mellitus-part 1: a meta-analysis of randomised clinical trials. Diabetes and Metabolism 2004 30 6 487 496 2-s2.0-11244294737 (Pubitemid 40070350)
18. Elliott W. J., Meyer P. M., Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 369 9557 201 207 2-s2.0-33846294746 10.1016/S0140-6736(07)60108-1 (Pubitemid 46111014)
19. Zillich A. J., Garg J., Basu S., Bakris G. L., Carter B. L., Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006 48 2 219 224 2-s2.0-33748147006 10.1161/01.HYP.0000231552. 10054.aa (Pubitemid 44309815)
20. Bia M. J., DeFronzo R. A., Extrarenal potassium homeostasis. The American Journal of Physiology 1980 238 5 E421 E427 2-s2.0-0019556566
21. Fukao K., Shimada K., Hiki M., Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azeldipine and amlodipine on glucose tolerance and endothelial function-a crossover trial (AGENT). Cardiovascular Diabetology 2011 10 79 1 7
22. Padwal R., Mamdani M., Alter D. A., Hux J. E., Rothwell D. M., Tu K., Laupacis A., Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004 27 10 2458 2463 2-s2.0-4644333153 10.2337/diacare.27.10.2458 (Pubitemid 39281401)
23. Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., De Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L. H., Nieminen M. S., Omvik P., Oparil S., Wedel H., Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 9311 995 1003 2-s2.0-0037160968 10.1016/S0140-6736(02)08089-3 (Pubitemid 34286536)
24. Gillespie E. L., White C. M., Kardas M., Lindberg M., Coleman C. I., The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005 28 9 2261 2266 2-s2.0-24144490705 10.2337/diacare.28.9.2261 (Pubitemid 41242483)
25. Yusuf S., Ostergren J. B., Gerstein H. C., Pfeffer M. A., Swedberg K., Granger C. B., Olofsson B., Probstfield J., McMurray J. V., Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005 112 1 48 53 2-s2.0-21844434198 10.1161/CIRCULATIONAHA.104.528166 (Pubitemid 40962568)
26. Bosch J., Yusuf S., Gerstein H. C., Pogue J., Sheridan P., Dagenais G., Chiasson J. L., Diaz R., Avezum A., Lanas F., Probstfield J., Fodor G., Holman R. R., Effect of ramipril on the incidence of diabetes. The New England Journal of Medicine 2006 355 15 1551 1562 2-s2.0-33749590988 10.1056/NEJMoa065061 (Pubitemid 44550032)
27. Barzilay J. I., Gao P., Rydén L., Effects of telmisartan on glucose levels in people at high risk for cardiovascular dsease but free from diabetes: The TRANSCEND study. Diabetes Care 2011 34 9 1902 1907
28. Lithell H. O., Hyperinsulinemia, insulin resistance, and the treatment of hypertension. American Journal of Hypertension 1996 9 11 150S 154S 2-s2.0-0029823072 10.1016/0895-7061(96)00290-7 (Pubitemid 26383509)